George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I posted this the other day, but might have got lost in all the noise, but gives a very good recent example for those that haven't seen it, of the potential worth of SFX-01 for ARDS....Gla ;-)
........................
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Published: Nov 20, 2020
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to COVID-19. The company plans to launch a Phase III trial in non-COVID-19-related ARDS shortly after closing the deal. The drug is currently being evaluated in a Phase III trial in COVID-19-related ARDS.
https://www.biospace.com/article/novartis-inks-deal-with-mesoblast-for-remestemcel-l-for-covid-19-ards/
Might be worth keeping a close eye on Scottish numbers this time around, now that the trial is underway. Gla ;-)
Scottish numbers: 24 November 2020
Summary
771 new cases of COVID-19 reported
41 new reported death(s) of people who have tested positive
84 people were in intensive care yesterday with recently confirmed COVID-19
1,197 people were in hospital yesterday with recently confirmed COVID-19
11,316 new tests for COVID-19 that reported results – 8.6% of these were positive
Lol....i beg your pardon????........ Ha ha ha ha ha ......i've got loads to sell matey, but not until the market cap is valued at several £100 million......which is highly possible in the next few months on positive data from the Covid/ARDS trial. Gla Holders ;-)
Back to double figures plus this week imho...............On and UP................the current sp offers a rare opportunity for truly transformational returns if all goes to plan.....Gla holders...hold on tight and enjoy the ride...UPwards!!! ;-)
Interesting - so Moneymunch is the seller jimbren??
how much have you got to sell yet?
0
This will be back into double figures soon enough, as confirmation comes in of ongoing patient recruitment for SFX-01's Covid-19 patient trials which are underway at long last....any early reporting on positive indications will send this into orbit imho, and news on the rest of the pipeline could drop at anytime....the current sp could be the bargain of the century, if all goes to plan.....Gla holders...hold tight and enjoy the ride!!! ;-)
Ps here's a very recent example of Norvatis making an early move for a drug, still in phase 3 trials for ARDS, and so Top Line results not in yet...good or bad....something similar for Evgen highly plausible if phase 2 stage reports encouraging data...On and UP!!! :-)
.........
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Published: Nov 20, 2020By Mark Terry
lucarista / Shutterstock
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to COVID-19. The company plans to launch a Phase III trial in non-COVID-19-related ARDS shortly after closing the deal. The drug is currently being evaluated in a Phase III trial in COVID-19-related ARDS.
Under the terms of the deal, Novartis acquires exclusive worldwide rights to develop, commercialize and manufacture remestemcel-L for ARDS. They are paying Mesoblast $25 million up front and will invest $25 million in Mesoblast equity along with additional pre-commercialization milestone payments that could total $505 million and post-commercialization milestones up to $750 million. They are also eligible for royalties. Novartis will offer support for commercial manufacturing scale-up. Novartis also has an option to distribute the drug for graft versus host disease (GVHD) outside Japan. Both companies have rights to co-fund development and commercialization for other non-respiratory indications.
In addition, Novartis will reimburse Mesoblast up to $50 million on hitting specific milestones associated with the next-generation manufacturing processes using its proprietary media and three-dimensional bioreactors. Novartis will handle any capital expenditures needed to meet increased capacity for manufacturing.
Remestemcel-L is made up of culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. The companies believe it has immunomodulatory properties that can counteract the overactive immune reaction known as a cytokine storm that is linked to COVID-19 and other inflammatory conditions. They believe it down-regulates the production of pro-inflammatory cytokines and increased production of anti-inflammatory cytokines.
https://www.biospace.com/article/novartis-inks-deal-with-mesoblast-for-remestemcel-l-for-covid-19-ards/